Female hormones and thrombosis

Area of Science:

• Endocrinology
• Cardiovascular Medicine
• Thrombosis Research

Background:

• Exogenous hormones, including oral contraceptives (OCs) and postmenopausal hormone replacement therapy (HRT), are widely used by millions globally.
• Previous research indicates potential cardiovascular and thrombotic risks associated with hormone use.

Purpose of the Study:

• To evaluate the risks of venous thrombosis, myocardial infarction (MI), and stroke associated with exogenous hormone use, specifically OCs and HRT.
• To identify specific patient populations and hormonal formulations that carry a higher risk.

Main Methods:

• Review of existing studies and clinical data on women using OCs or HRT.
• Analysis of risk factors including duration of use, specific hormone types (e.g., third-generation OCs), and pre-existing conditions like coagulation abnormalities and prior venous thrombosis.

Main Results:

• OCs increase the risk of venous thrombosis, MI, and stroke, with the highest risk observed in the first year of use.
• Third-generation OCs (desogestrel, gestodene) and coagulation abnormalities significantly elevate venous thrombotic risk.
• HRT also increases venous thrombosis risk, particularly within the first year and in women with coagulation issues or a history of thrombosis.
• Randomized trials did not confirm a cardioprotective effect of postmenopausal hormones.

Conclusions:

• Exogenous hormone use, both OCs and HRT, is associated with significant thrombotic and cardiovascular risks.
• Risk stratification is crucial, considering hormone type, duration of use, and individual patient factors like coagulation status.
• The potential benefits of HRT on cardiovascular health remain unproven by randomized trials.